Strengthening Resilience, Strategic Independence, and Safety Through Biotech We would like to stress the importance of linking the future EU Biotech Act strongly to the need for strengthening broad societal resilience, strategic independence and safety of the European Union, especially in the health area. We applaud the European Commission on the initiative to strengthen biotech in Europe.
SLS
Scalable Life Sciences
Company · Netherlands · EU Transparency Register 996467721056-18
1
position filed
in the 665 files tracked
1
legislative file
of 665 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track Scalable in PolicySpeak: request access →
Work at Scalable Life Sciences? so we know who speaks for it.
Their record over time
Scalable Life Sciences filed 1 position on 11 Jun 2025, across 1 of the 665 legislative files tracked here.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Scalable Life Sciences next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Scalable Life Sciences’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.